Chester County News and Community Website
What This Means for You More than 500 new jobs are expected in Montgomery County over the next 12 years. The state will provide up to $41.5 million in financial …
Johnson & Johnson to Invest $1 Billion in Montgomery County Cancer Drug Facility Read More
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) reported new real-world evidence showing that patients with metastatic castration-sensitive prostate cancer who began treatment with ERLEADA without chemotherapy experienced a sharply …
Real-World Study Finds ERLEADA Cuts Death Risk in Advanced Prostate Cancer Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved a new frontline treatment option for adults newly diagnosed with multiple myeloma who …
FDA Clears Johnson & Johnson Myeloma Combo, Expanding Frontline Care Read More
HARRISBURG, PA — Pennsylvania is quietly pulling off what many states only promise: keeping new businesses alive long enough to thrive. New federal data shows that 56 percent of companies …
Pennsylvania’s Business Boom Defies the Odds as Survival Rates Soar Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical hurdle in systemic lupus erythematosus, delivering the first positive Phase 2b …
J&J’s Lupus Breakthrough Sets the Stage for a High-Stakes Phase 3 Push Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the first and only subcutaneous therapy for patients with EGFR-mutated non-small …
FDA Clears Five-Minute Lung Cancer Shot, Redefining EGFR Treatment Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved an expanded indication for AKEEGA, clearing the first FDA-approved precision medicine combination for …
FDA Clears Breakthrough Precision Combo for Aggressive Prostate Cancer Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as the first-ever treatment for adults with …
FDA Approves First Treatment for High-Risk Smoldering Multiple Myeloma Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced plans to launch the first-ever head-to-head study comparing its FcRn blocker IMAAVY™ (nipocalimab-aahu) with efgartigimod in adults living with generalized …
Johnson & Johnson Launches First Head-to-Head Study of IMAAVY in Myasthenia Gravis Read More SPRING HOUSE, PA — A new U.S. study from Johnson & Johnson (NYSE: JNJ) reveals that most people living with psoriasis — and their healthcare providers — strongly prefer effective …
New Study Finds Psoriasis Patients Favor Oral Treatments Over Injections Read More